Why the study?
Does oxprenolol improve symptoms in patients with severe recurrent cardiac pain, arrhythmias, or hypertrophic subaortic stenosis?
Does oxprenolol improve symptoms in patients with severe recurrent cardiac pain, arrhythmias, or hypertrophic subaortic stenosis?
Oxprenolol is an effective beta-blocker for managing severe cardiac pain and arrhythmias, with a low incidence of significant side effects over a two-year period.
Answers are grounded in this paper and cite their sources.
May support oxprenolol for refractory cardiac symptoms; hypothesis-generating and should not change practice without randomized data.
Oxprenolol (“Trasicor”), a potent beta-adrenergic blocking drug, has been administered in a daily dosage of 40 to 240 mg to 84 patients suffering from severe recurrent cardiac pain (45 patients), arrhythmias (37 patients) and left ventricular outflow tract obstruction due to hypertrophic subaortic stenosis (two patients). The condition of 76% of patients with cardiac pain improved during treatment. The drug was useful in the control of sinus tachycardia, the suppression of ectopic beats and the prevention of paroxysmal supraventricular tachycardia. Cardiac failure developed during oxprenolol treatment in two cases; no other significant side effects were observed during the two years of this trial. Oxprenolol appears to be a valuable addition to the range of beta-adrenergic blocking drugs currently available.
No takes yet. Share an insight, caveat, or question.
Bauer et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: